Last update March 16, 2021

Polyethylene Glycol (PEG)

Very Low Risk

Safe. Compatible. Minimal risk for breastfeeding and infant.

An osmotic laxative which is not absorbed.
Polymers whose molecular weight is between 1,000 and 35,000 daltons. The number added to the term "macrogol" defines its molecular weight, eg: macrogol 3350.
Oral administration.

Since the last update we have not found published data on its excretion in breast milk.

Its pharmacokinetic data (zero oral bioavailability and high molecular weight) make transfer to milk in significant quantities unlikely.

Its zero oral bioavailability prevents its transfer to the infant’s plasma via ingested breast milk.

Experts and scientific associations, as well as the manufacturer, consider it compatible with breastfeeding (Gharehbaghi 2016, Müller 2013, AEMPS 2010, Mahadevan 2006).


We do not have alternatives for Polyethylene Glycol (PEG) since it is relatively safe.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Polyethylene Glycol (PEG) is also known as

Polyethylene Glycol (PEG) in other languages or writings:


Polyethylene Glycol (PEG) belongs to this group or family:


Main tradenames from several countries containing Polyethylene Glycol (PEG) in its composition:


Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 3.350 - 4.000 daltons


  1. Gharehbaghi K, Gharehbaghi DR, Wierrani F, Sliutz G. [Treatment of Chronic Functional Constipation during Pregnancy and Lactation]. Z Geburtshilfe Neonatol. 2016 Abstract
  2. Müller-Lissner S. Pharmacokinetic and pharmacodynamic considerations for the current chronic constipation treatments. Expert Opin Drug Metab Toxicol. 2013 Abstract
  3. Müller-Lissner S. [Pharmacological treatment of constipation]. Internist (Berl). 2013 Abstract
  4. AEMPS. Macrogol. Ficha técnica. 2010 Full text (in our servers)
  5. Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul;131(1):283-311. Review. Abstract Full text (link to original source) Full text (in our servers)

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by AELAMA of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM